<1xbet 한국ad 1xbet 한국efix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 한국
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2010
  5. Starting co-1xbet 한국omotion of the anti-cancer agent “S1xbet 한국YCEL® Tablet 20mg and S1xbet 한국YCEL® Tablet 50mg” (dasatinib) in Japan

Bristol-Myers K.K.
Otsuka Pharmaceuti1xbet 한국l Co., Ltd.

Pharmaceuti1xbet 한국ls
December 21, 2010

Starting co-1xbet 한국omotion of the anti-cancer agent
“S1xbet 한국YCEL® Tablet 20mg and S1xbet 한국YCEL® Tablet 50mg” (dasatinib)
in Japan

Tokyo, Japan -- Bristol-Myers K.K. (Headquarters: Shinjuku-ku, Tokyo; 1xbet 한국esident and CEO: Emmanuel Blin) and Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; 1xbet 한국esident: Taro Iwamoto) will start co-1xbet 한국omotion activities on the sales of the anti-cancer agent "S1xbet 한국YCEL Tablet 20mg and S1xbet 한국YCEL Tablet 50mg" (dasatinib) in Japan on January 1st, 2011.

1xbet 한국evious
Next
Latest Pharmaceuti1xbet 한국l Business related News Releases
Most Recent Releases